Human Antithrombin III (AT3) AssayMax™ELISA Kit Human Antithrombin III (AT3) AssayMax™ELISA Kit
Move your mouse over image or click to enlarge

Human Antithrombin III (AT3) AssayMax™ELISA Kit

This assay employs a quantitative enzyme immunoassay technique that measures the specified antigen in samples.

Cat# Size Price Qty Buy
EA3303-1 96 Well Plate £276.25

Additional Information

Property Value or Rating
Manufacturer Assaypro, LLC.
Product Type AssayMax™ ELISA Kits
Species Human
Assay Format Competitive ELISA
Product Size 96 Well Plate
Range 0.063-4 ug/ml
Plex Number 1
Storage Refer to component labels for details
Entrez Gene 462
Omim 107300
UniProt P01008
UniGene Hs.75599
Special Notes For Research Use Only, Not To Be Used For Diagnostic Purposes
References * Oberbach A et al. (2011) Combined Proteomic and Metabolomic Profiling of Serum Reveals Association of the Complement System with Obesity and Identifies Novel Markers of Body Fat Mass Changes. J Proteome Res. 10(10):4769-88 
* Saleh AAW et al. (2014) Markers of Inflammation and Thrombophilia in Psoriasis. Med. J. Cairo Univ. 82(1):127-131 
* Sehgal A et al. (2015) An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nature Medicine 21(5):492-497 
* Nair JK et al. (2017) Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc 
* Schochl H et al. (2017) Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsis. Crit Care. 21(1):51 

" title="

* Oberbach A et al. (2011) Combined Proteomic and Metabolomic Profiling of Serum Reveals Association of the Complement System with Obesity and Identifies Novel Markers of Body Fat Mass Changes. J Proteome Res. 10(10):4769-88 
* Saleh AAW et al. (2014) Markers of Inflammation and Thrombophilia in Psoriasis. Med. J. Cairo Univ. 82(1):127-131 
* Sehgal A et al. (2015) An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nature Medicine 21(5):492-497 
* Nair JK et al. (2017) Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc 
* Schochl H et al. (2017) Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsis. Crit Care. 21(1):51 

" target="_blank">

* Oberbach A et al. (2011) Combined Proteomic and Metabolomic Profiling of Serum Reveals Association of the Complement System with Obesity and Identifies Novel Markers of Body Fat Mass Changes. J Proteome Res. 10(10):4769-88 
* Saleh AAW et al. (2014) Markers of Inflammation and Thrombophilia in Psoriasis. Med. J. Cairo Univ. 82(1):127-131 
* Sehgal A et al. (2015) An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nature Medicine 21(5):492-497 
* Nair JK et al. (2017) Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc 
* Schochl H et al. (2017) Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsis. Crit Care. 21(1):51 

Related Documents